07:00 Tue 02 Mar 2021
OptiBiotix Health - Director Appointment
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director Appointment
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces that further to the announcement made on
Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the following information is disclosed in respect of
Current Appointments |
Appointments in the last five years |
Harwood Film Partnership LLP |
Commonwealth Parliamentary Association ( |
Peal Gas LLC |
G-Volution Limited |
|
South Coast Regeneration & Investment Property Co Limited |
In
There is no further information regarding
"The Company anticipate that there will be further additions and changes to the Board and management teams as it continues to grow sales, expand into international markets and commercialises its next generation products."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
The Directors of the Company accept responsibility for the content of this announcement.
For further information, please contact:
OptiBiotix Health plc |
|
|
Contact via Walbrook below |
|
|
Cairn Financial Advisers LLP (NOMAD) |
Tel: 020 7213 0880 |
|
|
finnCap (Broker) |
Tel: 020 7220 0500 |
|
|
Walbrook PR Ltd |
Mob: 07876 741 001 |
|
|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI) is a biotechnology company formed in
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than seventy international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE